Skip to main content

Table 3 PFS and survival results (ITT population)

From: A phase II study of cisplatin with intravenous and oral vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy with oral vinorelbine and cisplatin for locally advanced non-small cell lung cancer

  ITT population n = 70
Median progression free survival, months 14.58 [95% CI; 10.97-18.75]
Progression free survival rate at 12 months, % 58.6 [95% CI; 47.0-70.1]
Median overall survival, months 17.08 [95% CI; 13.56-29.57]
Survival rate at 6 months, % 88.6 [95% CI; 81.1-96.0]
Survival rate at 12 months, % 68.6 [95% CI; 57.7-79.4]
Survival rate at 18 months, % 43.4 [95% CI; 31.3-55.6]
Survival rate at 24 months, % >37*
  1. *95% CI was not estimated (data were not mature).